Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000193

Drug Information
NameEpirubicin
SynonymsEpirubicine; Epirubicin; Pidorubicina [INN-Spanish]; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; SMR000466308; AC1Q6JIV; Epirubicin (INN); Ellence; 4'-Epiadriamycin; 4'-Epi-DXR; Epiadriamycin; 56390-09-1 (hydrochloride); 56420-45-2; IMI 28; Epirubicina [INN-Spanish]; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; Ridorubicin; Epirubicinum [INN-Latin]; Triferric doxorubicin; Pidorubicinum [INN-Latin]; Pidorubicine [INN-French]; NChemBio.2007.10-comp15; Farmorubicin (TN); Pidorubicinum; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; Epidoxorubicin; 4'-epi-DX; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; CID41867; CCRIS 2261; 57918-25-9; CHEMBL417; AC1L26NP; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-epi-Doxorubicin; NSC256942; UNII-3Z8479ZZ5X; Epirubicinum [Latin]; WP 697; MLS000759412; NSC 256942; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; C11230; 4'-epidoxorubicin; LS-93992; Epirubicin [INN:BAN]; Epirubicina; Epirubicine [French]; 56390-09-1; 4-Epidoxorubicin; Pidorubicine; Pidorubicin; HSDB 6962; Epirubicinum; Epirubicina [Spanish]; Epirubicine [INN-French]; CHEBI:47898; Pharmorubicin Pfs; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; NSC-256942; C27H29NO11; Pidorubicina; LS-187190; DB00445; BRN 1445813; Epi-DX; D07901
Trade NameEllence; Pharmorubicin; Epirubicin Ebewe
CompanyPfizer Pharmaceuticals
IndicationCancers
[ICD9: 140-229   ICD10: C00-C96]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-
29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)2
5(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,1
3-,15-,17-,22-,27-/m0/s1
InChIKeyAOJJSUZBOXZQNB-VTZDEGQISA-N
Canonical SMILESCC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)
CO)O)N)O    
Isomeric SMILESC[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)
C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 56420-45-2
FormulaC27H29NO11
PubChem Compound IDCID 41867.
PubChem Substance IDSID 13409.
ChEBI47898;
SuperDrug ATC IDL01DB03
SuperDrug CAS ID056420452;
TargetDNA topoisomerase IIInhibitor[2]
Ref 1New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31. To Reference
Ref 2Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009 May 6;101(9):644-50. Epub 2009 Apr 28. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543